-       Clinical Trials 
- April 2025
-  200 Pages 
- Global 
   From       €1789EUR$2,000USD£1,574GBP 
      €2236EUR$2,500USD£1,967GBP 
            -       Drug Pipelines 
- April 2025
-  60 Pages 
- Global 
   From       €1431EUR$1,600USD£1,259GBP 
      €1789EUR$2,000USD£1,574GBP 
            -       Report 
- December 2024
-  112 Pages 
- Global 
   From       €2826EUR$3,160USD£2,486GBP 
      €3533EUR$3,950USD£3,108GBP 
          -       Report 
- March 2025
-  200 Pages 
- Global 
   From       €2227EUR$2,490USD£1,959GBP 
          -       Report 
- May 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
             -       Report 
- April 2025
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Clinical Trials 
- April 2025
-  80 Pages 
- Global 
   From       €1431EUR$1,600USD£1,259GBP 
      €1789EUR$2,000USD£1,574GBP 
            -       Clinical Trials 
- April 2025
-  40 Pages 
- Global 
   From       €894EUR$1,000USD£787GBP 
      €1118EUR$1,250USD£983GBP 
            -       Clinical Trials 
- April 2025
-  120 Pages 
- Global 
   From       €1431EUR$1,600USD£1,259GBP 
      €1789EUR$2,000USD£1,574GBP 
          -       Report 
- October 2024
-  200 Pages 
- Global 
   From       €3354EUR$3,750USD£2,950GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- February 2024
-  120 Pages 
- Asia Pacific 
   From       €3542EUR$3,960USD£3,116GBP 
      €4428EUR$4,950USD£3,895GBP 
          -       Report 
- November 2023
-  154 Pages 
- Global 
   From       €2236EUR$2,500USD£1,967GBP 
          -       Report 
- September 2024
-  98 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
          -       Report 
- October 2023
-  102 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
       
      Cirrhosis is a serious liver disorder caused by long-term damage to the liver. It is characterized by scarring of the liver tissue, which can lead to liver failure. Treatment for cirrhosis typically involves medications to reduce inflammation, improve liver function, and reduce the risk of complications. Drugs used to treat cirrhosis include diuretics, antibiotics, antivirals, and immunosuppressants.
The cirrhosis drug market is a subset of the larger liver and kidney disorders drugs market. It is    composed of drugs used to treat cirrhosis and its associated complications. These drugs are used to reduce inflammation, improve liver function, and reduce the risk of complications.
Some companies in the cirrhosis drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less   Read more